Rationale: Myocyte enhancer factor 2 (MEF2) transcription factors drive the genetic reprogramming that precipitates pathological cardiac hypertrophy and remodeling. Class II histone deacetylase (HDAC) isoforms, such as HDAC5, act as signal-responsive repressors of MEF2 activity in cardiac myocytes and their nuclear export provides a key mechanism for the neurohormonal induction of such activity.
A substantial body of evidence indicates that the activity of myocyte enhancer factor 2 (MEF2) transcription factors is a critical driver of the pathological cardiac hypertrophy and remodeling processes that culminate in heart failure, in both acquired 1 and genetic 2 forms of the disease. An extensive series of studies in recent years, particularly in the Olson laboratory, have revealed that class II histone deacetylase (HDAC) isoforms, such as HDAC4 and HDAC5, act as signal-responsive repressors of nuclear MEF2 activity in cardiac myocytes and that their spatial regulation provides a key mechanism for the neurohormonal control of such activity. 3, 4 The compelling scheme that has emerged is that HDAC4 and HDAC5 are direct substrates for serine/threonine protein kinases of the Ca 2ϩ /calmodulin-dependent kinase (CaMK) superfamily, such as CaMKII 5 and protein kinase D (PKD), 6 and that the phosphorylation by such kinases of conserved residues that flank nuclear localization signal domains in HDAC4/5 leads to their exclusion from the nucleus and consequent derepression of MEF2 activity. [7] [8] [9] [10] [11] [12] Recent studies suggest that protein kinase A (PKA) may also regulate MEF2 activity through HDAC-mediated mechanisms, but in an opposing manner, by promoting HDAC5 nuclear retention 13 or HDAC4 proteolytic cleavage. 14 Finally, there is emerging evidence that HDAC nuclear localization may be regulated additionally by a novel, phosphorylationindependent mechanism, through redox-dependent modification of reactive cysteine residues in HDAC4. 15 How these different pathways are integrated in the neurohormonal regulation of HDAC nuclear localization and thus MEF2 activity is currently unclear, with the picture further complicated by the existence of regulatory crosstalk between such signaling pathways (as exemplified by PKA-mediated inhibition of PKD in cardiac myocytes 16, 17 ). Furthermore, although the frequent use of noncardiac cell lines and neonatal cardiac myocyte preparations has undoubtedly provided valuable mechanistic insights, 7, 8, [13] [14] [15] the extrapolation of such information to adult myocardium is not always straightforward, not least because of the developmental changes that occur in relevant signaling molecules, such as PKD. 18 The principal objective of the present study, therefore, was to explore the mechanism(s) through which clinically relevant neurohormonal stimuli may regulate the phosphorylation and subcellular localization of HDAC isoforms, with particular focus on HDAC5 and the role of PKD, exclusively in adult cardiac myocytes.
Our findings reveal that PKD is a critical mediator of HDAC5 phosphorylation in response to endothelin-1 (ET1) stimulation but plays a relatively insignificant role in regulating HDAC4 phosphorylation. Furthermore, PKD-mediated phosphorylation is necessary to induce HDAC5 nuclear export on ET1 stimulation. An important and unexpected novel finding was that ␤ 1 -adrenergic receptor (␤ 1 -AR) stimulation by isoproterenol (ISO) also induces HDAC5 nuclear export, but this occurs through a phosphorylationindependent, oxidation-mediated mechanism that is associated with reduced HDAC5 phosphorylation. Furthermore, although ET1 and ISO both induce HDAC5 nuclear export, with a similar time course and to a comparable extent but through distinct mechanisms, the latter stimulus induces a markedly greater increase in MEF2 activity. We conclude that PKD-mediated HDAC5 phosphorylation and nuclear export are unlikely to be of major pathophysiological importance in the presence of sympathetic activity with intact ␤ 1 -AR signaling, as these conditions would not only counteract HDAC5 phosphorylation (by inhibiting PKD activation and by inducing HDAC5 dephosphorylation) but also induce HDAC5 nuclear export through a novel phosphorylationindependent, oxidation-mediated mechanism. The implications of our data are discussed, in the context of other pertinent evidence from the literature, with regard to both the therapeutic potential of PKD inhibition and the mechanisms underlying the undisputed therapeutic efficacy of ␤ 1 -AR antagonists in patients with heart failure.
Methods
Expanded methodology is provided in the Online Supplement. Previously published methods were used for key techniques such as the isolation and culture of ventricular myocytes from the adult rat heart, 19 adenoviral vector construction and myocyte infection, 20 in vitro kinase assays for inhibitor screening, 21 immunoblot analysis, 22 and assessment of GFP-HDAC5 subcellular localization by fluorescence microscopy. 23 Quantitative data are given as meanϮSEM and intergroup comparisons were by analysis of variance (ANOVA), followed by the Bonferroni test. PϽ0.05 was considered significant.
Results
We have reported previously that a phospho-specific antibody directed at pSer498 HDAC5 detects increased phosphorylation of multiple proteins, which are likely to represent distinct HDAC isoforms, in response to ET1-induced PKD activation in adult rat ventricular myocytes (ARVM). 17 The motif around Ser498 in HDAC5 (PLSRTQSSPL; italic type indicates the phosphorylated residue) is conserved among other class II HDAC isoforms, including HDAC4 (Ser467, PLGRTQSAPL), and conforms to the optimal PKD substrate motif (an aliphatic amino acid [L, V, or I] at the -5 position and a basic amino acid [K or R] at the -3 position, relative to the phosphorylated S residue 24, 25 ). The same holds true also for the motifs around Ser259 in HDAC5 and its equivalent Ser246 in HDAC4 (both PLRKTASEPN). Furthermore, phosphorylation of these residues, which flank a nuclear localization signal domain in both HDAC4 and HDAC5, has been causally implicated in the neurohormonal induction of HDAC nuclear export and thereby the disinhibition of MEF2-driven transcriptional reprogramming that facilitates myocyte hypertrophy. 4, 26 We therefore explored the individual regulation of HDAC4 and HDAC5 in ARVM through heterologous expression of their FLAG epitope-tagged variants (FLAG-HDAC4 and FLAG-HDAC5), using a newly described selective PKD inhibitor (identified as compound 12a 27 or bipyridyl PKD inhibitor [BPKDi] 28 ) to confirm the role of PKD activity in their ET1induced phosphorylation. In an initial step, we extended the recent pharmacological characterization of BPKDi 27,28 by screening it against a larger panel of Ͼ120 protein kinases using validated in vitro kinase assays, 21 which underscored the inhibitor's remarkable selectivity for PKD (Online Table I ). We also confirmed the ability of BPKDi to inhibit PKD activity in ARVM at concentrations Ͼ1 mol/L (Online Figure I) , with the lower potency reflecting the higher ATP concentration in cells relative to that used for in vitro kinase assays, as observed also for other ATP-competitive kinase inhibitors. 29 As shown in Figure 1A , FLAG-HDAC4 showed high basal phosphorylation at the site detected by the pSer259 HDAC5 antibody (likely to reflect Ser246 phosphorylation) and the signal did not increase significantly after ET1 stimulation, whereas phosphorylation at the site detected by the pSer498 HDAC5 antibody (likely to reflect Ser467 phosphorylation) increased significantly after ET1 stimulation. Pretreatment with BPKDi (3 mol/L) did not affect FLAG-HDAC4 phosphorylation at Ser246 basally or after ET1 stimulation ( Figure 1A) . Pretreatment with the PKD inhibitor also did not affect basal FLAG-HDAC4 phosphorylation at Ser467 and only partially attenuated its response to ET1 stimulation ( Figure 1A) . In contrast, FLAG-HDAC5 phosphorylation at both Ser259 and Ser498 showed a large and significant increase after ET1 stimulation ( Figure 1B ). Pretreatment with BPKDi did not affect basal FLAG-HDAC5 phosphorylation at Ser259 or Ser498 but completely abolished the increases in such phosphorylation in response to ET1 stimulation ( Figure  1B) . These data indicate that in response to ET1 stimulation in ARVM, PKD activity is a key mediator of HDAC5 phosphorylation at both Ser259 and Ser498, but plays a relatively insignificant role in modifying HDAC4 phosphorylation at either of its equivalent regulatory sites.
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We then explored the potential impact of ␤-AR-mediated inhibition of PKD activation, as described in our previous work, 16, 17 on the regulation of HDAC4 and HDAC5 phosphorylation. A 10-minute exposure to ISO (100 nmol/L) had no significant impact on FLAG-HDAC4 phosphorylation at Ser246 or Ser467, in the absence or presence of subsequent ET1 stimulation ( Figure 1C ). In contrast, ISO reduced the phosphorylation of FLAG-HDAC5 at Ser259 and Ser498, both basally and after ET1 stimulation ( Figure 1D ). These findings suggest that ␤-AR-mediated pathways counteract the phosphorylation of HDAC5 but not HDAC4 in the absence and presence of subsequent ET1 stimulation, through mechanisms that may involve reduced PKD activation. 16, 17 On the basis of the greater responsiveness of HDAC5 phosphorylation to regulation by ET1-and ISO-activated pathways, in particular by cellular PKD activity, we subsequently focused on neurohormonal regulation of the phosphorylation and subcellular localization of this HDAC isoform.
To allow the direct monitoring of its subcellular localization in ARVM by fluorescence microscopy, we expressed HDAC5 as a green fluorescent protein (GFP) fusion protein (GFP-HDAC5). 7 In keeping with our observations with heterologously expressed FLAG-HDAC5 ( Figure 1B and 1D), ET1 stimulation induced a robust increase in GFP-HDAC5 phosphorylation at both Ser259 and Ser498, with the response peaking by 30 minutes (Figure 2 ). GFP-HDAC5 phosphorylation at both sites was significantly attenuated by ␤-AR stimulation by a 10-minute exposure to 100 nmol/L ISO, in the absence of and during subsequent ET1 stimulation ( Figure 2 ). When the subcellular localization of GFP-HDAC5 was monitored, it was found to be predominantly nuclear under basal conditions, and this localization was unaltered over a 60-minute period in vehicle-treated control cells ( Figure 3A) . In contrast, ET1 stimulation induced a progressive export of GFP-HDAC5 from the nucleus into the cytoplasm ( Figure 3A) , which is consistent with previous observations in neonatal rat ventricular myocytes (NRVM) 7, 9, 28 and ARVM, 23 with a time course that paralleled the increases in GFP-HDAC5 phosphor- ylation at Ser259 and Ser498 ( Figure 2) . Surprisingly, however, ISO also induced the nuclear export of GFP-HDAC5 with a time course similar to that seen with ET1 ( Figure 3A ), despite the opposing effects of the 2 stimuli on GFP-HDAC5 phosphorylation at Ser259 and Ser498 ( Figure 2 ). The effect of the combination of ISO and ET1 on GFP-HDAC5 subcellular localization was indistinct from that of either stimulus alone ( Figure 3A) . Importantly, pretreatment of ARVM with BPKDi completely inhibited the ET1-induced nuclear export of GFP-HDAC5, indicating a predominantly PKD-mediated mechanism for this response (in partial distinction from the situation in rabbit ventricular myocytes, where a nonspecific PKD inhibitor incompletely inhibited such translocation 30 ), but it had no effect on similar GFP-HDAC5 translocation in response to ISO ( Figure  3B ). Nevertheless, ISO-induced GFP-HDAC5 nuclear export was inhibited by the selective ␤ 1 -AR antagonist atenolol ( Figure  3C ), confirming a ␤ 1 -AR-mediated mechanism for this PKDindependent effect. Complementary "dose-response" studies revealed that ISO triggered the nuclear export of GFP-HDAC5 even at a low concentration of 1 nmol/L (Online Figure II) , which was also the minimum concentration that inhibited PKD activation during subsequent ET1 stimulation (Online Figure  III) . Importantly, on sustained exposure, ET1 and ISO were found to each induce a significant increase in cellular MEF2 activity, as measured by an established luciferase reporter assay ( Figure 4 ), in conjunction with their common ability to acutely induce HDAC5 nuclear export ( Figure 3A) , albeit through apparently distinct mechanisms ( Figure 3B ). Interestingly, however, the increase in MEF2 activity was greater in response to ISO than to ET1 (Figure 4 ), suggesting the involvement of additional mechanisms.
To our knowledge, this is the first report of ␤ 1 -AR stimulation leading to HDAC5 nuclear export in adult cardiac myocytes. To the contrary, recent evidence from experiments in Cos7 cells and NRVM suggests that increased activity of protein kinase A (PKA, also known as cAMP-dependent protein kinase), which is a key downstream mediator of ␤ 1 -AR signaling, facilitates the nuclear retention of HDAC5. 13 The same study also identified Ser280 in HDAC5 as a direct PKA target whose phosphorylation may be causally involved in PKA-mediated nuclear retention, and showed that a commercially available phospho-Ser/Thr PKA substrate antibody is able to detect PKA-mediated HDAC5 phosphorylation at this site. 13 We therefore used such an antibody to explore whether ISO induces GFP-HDAC5 phosphorylation at Ser280 in ARVM. This approach revealed no increase in GFP-HDAC5 phosphorylation after ISO stimulation (in fact, GFP-HDAC5 was not detected by this antibody under any condition), although increased phosphorylation of multiple other PKA substrate proteins was readily evident (Online Figure IV) . These findings suggest that ␤-AR stimulation by ISO does not induce PKA-mediated HDAC5 phosphorylation at Ser280 in ARVM. We then used the membrane permeable PKA-inhibitory peptide 14 to 22 amide (PKI) 31 to explore the role of PKA in ␤-AR-mediated regulation of HDAC5 nuclear export. Pretreatment with PKI had no significant effect on ISO-induced GFP-HDAC5 nuclear export (Online Figure V) , suggesting that this effect occurs independently of PKA activity.
An alternative pathway through which the cardiac actions of ␤-AR stimulation are mediated is through the activation of Ca 2ϩ /calmodulin-dependent kinase II (CaMKII). 32 On the basis that HDAC5 contains numerous putative phosphorylation sites 33 and the possibility that ␤ 1 -AR stimulation may induce HDAC5 nuclear export through CaMKII-mediated phosphorylation of residue(s) other than Ser259, Ser280 and ARVM maintained in culture were infected with AdV-GFP-HDAC5 (MOI 10 pfu/cell) and exposed to ET1 (100 nmol/L) for 0 (control), 10, 30, or 60 minutes, after pretreatment with ISO (100 nmol/L) or vehicle (veh) for 10 minutes. Ser498 (which show reduced or unaltered phosphorylation on ISO stimulation), we next explored the effects of the CaMKII inhibitor KN93 on ISO-induced responses. Pretreatment of ARVM with KN93 to selectively inhibit ISO-induced CaM-KII activation (Online Figure VI) abolished ISO-induced GFP-HDAC5 nuclear export ( Figure 5A ). Importantly, however, a similar effect was seen also with the inactive KN93 congener KN92 ( Figure 5A ) that does not affect ISO-induced CaMKII activation (Online Figure VI) , indicating that the common ability of KN93 and KN92 to suppress the ISOinduced response occurred through a mechanism that is distinct from CaMKII inhibition. ISO stimulation led to a similar reduction in GFP-HDAC5 phosphorylation at Ser259 and Ser498 in the absence or presence of pretreatment with KN93 ( Figure 5B ). Furthermore, unlike KN93 and KN92 ( Figure 5A) , pretreatment with the membrane permeable CaMKII-selective autocamtide 2-related inhibitory peptide 34 had no significant effect on ISO-induced GFP-HDAC5 nuclear export (Online Figure VII) . These findings indicate that CaMKII does not play a key role in ␤-AR-mediated regulation of GFP-HDAC5 phosphorylation (at Ser259 and Ser498) or nuclear localization. We further explored the potential role of phosphorylation in ISO-induced GFP-HDAC5 nuclear export by additional approaches. First, we used a GFP-HDAC5 mutant in which Ser259 and Ser498 of HDAC5 were replaced by nonphosphorylatable Ala. As expected, the Ser259/498Ala mutations completely abrogated ET1-induced phosphorylation at the pertinent sites (Online Figure VIII) as well as ET1-induced nuclear export ( Figure 6A ). In contrast, ISO retained its ability to induce significant nuclear export of GFP-HDAC5 Ser259/498Ala ( Figure 6A ). These findings definitively confirm that, unlike the ET1-induced response, ISO-induced GFP-HDAC5 nuclear export occurs independently of altered HDAC5 phosphorylation at Ser259 and Ser498. Second, we used a non-site-specific approach to explore ISO-induced changes in GFP-HDAC5 phosphorylation, through PhosTag phosphate affinity SDS-PAGE. 35 This analysis revealed an ISO-induced reduction in overall GFP-HDAC5 phosphorylation status ( Figure 6B ). Taken together, the above findings indicate that ␤-AR-mediated HDAC5 nuclear export does not occur through increased HDAC5 phosphorylation.
Irrespective of the molecular mechanism(s) underlying ␤-AR-mediated GFP-HDAC5 nuclear export, our findings indicate that this process is inhibited robustly by methoxybenzenesulfonamide derivatives of the KN93/92 family. We therefore took advantage of the ability of KN93 to inhibit ISO-induced GFP-HDAC5 nuclear export to investigate the potential impact of ␤-AR-mediated inhibition of PKD activation on ET1-induced nuclear export of this HDAC isoform. Importantly, KN93 per se did not inhibit ET1-induced GFP-HDAC5 nuclear export (Online Figure IX, A) or phosphorylation at Ser259 and Ser498 (Online Figure IX, B) , which is consistent with our observations that these responses occur through a PKD-mediated mechanism ( Figure 1B and 3B) . The ability of ISO stimulation to inhibit ET1-induced PKD activation was unaltered in the presence of KN93 (Online Figure X, A) , reflecting our earlier data that such inhibitory crosstalk occurs through a cAMP/PKA-mediated pathway. 16, 17 Under these conditions, ISO stimulation failed to trigger GFP-HDAC5 nuclear export (confirming the data illustrated in Figure 5A ) and significantly inhibited such export in response to subsequent ET1 stimulation (Online Figure X, B) . These findings indicate that ␤-AR stimulation not only induces HDAC5 nuclear export through a phosphorylation-independent mechanism, but also inhibits ET1induced, PKD-mediated nuclear export of this HDAC isoform through a distinct mechanism, which may involve PKA-mediated inhibition of PKD activation. 16, 17 Finally, we explored the phosphorylation-independent mechanism through which ISO induces HDAC5 nuclear export. Recent evidence indicates that redox-dependent intramolecular disulfide bond formation between 2 reactive cysteine residues in HDAC4 can induce its nuclear export, in a phosphorylation-independent manner. 15 Furthermore, ISO stimulation of cardiac myocytes has been shown to induce the generation of reactive oxygen species (ROS), whose actions are counteracted by pretreatment with the antioxidant N-acetylcysteine (NAC). 36 We therefore determined the effects of pretreatment with NAC on ISO-induced GFP-HDAC5 nuclear export. Such pretreatment abolished ISOinduced GFP-HDAC5 nuclear export ( Figure 7A ). To specifically explore the role of cysteine oxidation, we additionally determined the impact of overexpressing the disulfide oxidoreductase protein thioredoxin-1 (Trx1), which reduces proteins with disulfide bonds through a thiol disulfide exchange reaction. Trx1 overexpression also inhibited ISOinduced GFP-HDAC5 nuclear export ( Figure 7B ). These findings indicate that ␤-AR-mediated HDAC5 nuclear export is likely to occur through a mechanism that involves ROSmediated cysteine oxidation and disulfide bond formation.
Discussion
The key findings of the present study are that (1) PKD is a critical mediator of HDAC5 phosphorylation at both Ser259 and Ser498 in response to ET1 stimulation but plays a relatively insignificant role in regulating HDAC4 phosphorylation at its corresponding residues; (2) PKD-mediated HDAC5 phosphorylation at Ser259 and Ser498 is necessary to induce HDAC5 nuclear export on ET1 stimulation; (3) ␤ 1 -AR stimulation by ISO also induces HDAC5 nuclear export, but this effect occurs through a phosphorylationindependent, oxidation-mediated mechanism that is associated with reduced HDAC5 phosphorylation; and (4) although ET1 and ISO both induce HDAC5 nuclear export, with a similar temporal profile and to a comparable extent but through distinct mechanisms, the latter stimulus induces a markedly greater increase in cellular MEF2 activity after sustained exposure.
Our novel findings described above suggest that ␤ 1 -ARmediated pathways play a dominant role in neurohormonal regulation of HDAC5 nuclear localization in ARVM, first by inducing phosphorylation-independent nuclear export and secondly by opposing phosphorylation-dependent nuclear export, the latter through reduced HDAC5 phosphorylation. Recent evidence from the Sadoshima laboratory has revealed a novel redox-dependent pathway for the regulation of HDAC4 nuclear localization, through the oxidation of Cys667 and Cys669 and the formation of a disulfide bond between these neighboring residues. 15 Notably, equivalent residues are conserved in HDAC5 (Cys696 and Cys698), raising the possibility that their oxidation in response to ␤ 1 -AR stimulation may provide the phosphorylation- Figure 6 . ISO-induced, but not ET1-induced, GFP-HDAC5 nuclear export occurs independently of increased HDAC5 phosphorylation. A, ARVM maintained in culture were infected with AdV-GFP-HDAC5-Ser259/498Ala (MOI 100 pfu/cell) and exposed to ET1 (100 nmol/L), ISO (1 nmol/L), or vehicle in controls (con) for 60 minutes. Figure shows quantitative data on nuclear:cytoplasmic fluorescence ratios, normalized to the basal value in each treatment group. *PϽ0.05 versus control (con) group (nϭ50 -60 cells). B, ARVM maintained in culture were infected with AdV-GFP-HDAC5 (MOI 10 pfu/cell) and exposed to ISO (1 nmol/L) or vehicle in controls (con) for 10 minutes. Samples were resolved by PhosTag phosphate-affinity SDS/ PAGE. Figure shows representative immunoblot for GFP, with the expected migration pattern of differentially phosphorylated GFP-HDAC5 moieties indicated.
independent mechanism that is suggested by our findings. This possibility is further enhanced by the recently reported ability of ISO to induce ROS generation in adult mouse cardiac myocytes, 36 as such an effect could potentially create the oxidative environment that facilitates the pertinent covalent modification of Cys696 and Cys698. Indeed, our data from myocytes pretreated with NAC or overexpressing Trx1 support a mechanism that involves ROS-mediated cysteine oxidation for ISO-induced HDAC5 nuclear export. Interestingly, our findings with KN93/KN92 additionally suggest that the pertinent mechanism is sensitive to inhibition by methoxybenzenesulfonamide derivatives. Such agents may provide not only useful experimental tools in identifying the key regulatory element(s) in this mechanism but also a chemical lead toward developing agents to selectively inhibit phosphorylation-independent HDAC5 nuclear export in response to ␤-AR stimulation. Importantly, ␤ 1 -AR stimulation in NRVM has been shown to induce fetal genes such as skeletal ␣-actin and atrial natriuretic peptide (whose increased expression through MEF2-mediated mechanisms is an established genetic marker of prohypertrophic transcriptional reprogramming 1 ), in a manner that is inhibited by KN93 (KN92 was not tested). 37 Additionally, chronic treatment of mice with KN93 has been shown to attenuate adverse ventricular remodeling and preserve contractile function after myocardial infarction. 38 Although CaMKII inhibition is likely to be an important mechanism underlying such beneficial effects of KN93 in vitro 37 and in vivo, 38 an additional contribution from reduced HDAC5 nuclear export through inhibition of the phosphorylation-independent mechanism that we have uncovered cannot be precluded.
The potential mechanism(s) underlying our novel finding that ISO stimulation reduces basal HDAC5 phosphorylation also warrant consideration. Although crosstalk inhibition of PKD activation 16, 17 may underlie the attenuation of ET1induced HDAC5 phosphorylation by ISO, it is unlikely to be a major mechanism of the ISO-induced reduction in basal HDAC5 phosphorylation, particularly since such an effect is not recapitulated by direct inhibition of PKD activity with BPKDi ( Figure 1) . A more likely mechanism is ISO-induced activation of phosphatase(s) that dephosphorylate HDAC5. Interestingly, a recent study in NRVM with the phosphatase inhibitor okadaic acid, used at a concentration that would be expected to selectively inhibit protein phosphatase type 2A (PP2A), indicates a role for PP2A activity in ␤ 1 -AR-mediated attenuation of PKD phosphorylation and thereby PKDmediated HDAC5 phosphorylation. 39 Other pertinent studies in the literature suggest that PP2A activity in cardiac myocytes is regulated by ␤-AR-mediated pathways, potentially through p21-activated kinase 1 40 or via altered localization of the PP2A targeting subunit B56␣. 41 Interestingly, we found that a mutated variant of HDAC5, in which both Ser259 and Ser498 were replaced by nonphosphorylatable Ala, was unresponsive to ET1-induced nuclear export (which is consistent with earlier observations in NRVM 7 ) but retained responsiveness to ISOinduced nuclear export. These observations suggest that the phosphorylation-independent, oxidation-mediated mechanism that is activated by ␤-AR stimulation predominates over phosphorylation-dependent mechanisms in regulating the subcellular compartmentalization of HDAC5, and is thus able to induce HDAC5 nuclear export despite reduced HDAC5 phosphorylation. In this context, it is important to note that Ala substitution of the equivalent phospho-acceptor residues in HDAC4 (Ser246 and Ser467) is similarly unable to inhibit HDAC4 nuclear export through cysteine oxidation. 15 An interesting distinction between ET1-induced and ISOinduced responses in ARVM in the present study is the markedly greater MEF2 activation that is seen with sustained exposure to ISO (Figure 4) , despite the comparable acute effects of the 2 agonists on HDAC5 nuclear export (Figure 3 ). This observation suggests that sustained ␤-AR stimulation may activate pathways in addition to HDAC5 nuclear export that also contribute to increased MEF2 activity. In this Figure 7 . ISO-induced GFP-HDAC5 nuclear export is mediated by oxidative signaling. A, ARVM maintained in culture were infected with AdV-GFP-HDAC5 (MOI 10 pfu/cell) and exposed to ISO (1 nmol/L) or vehicle in controls (con) for 60 minutes, after pretreatment with N-acetylcysteine (5 mmol/L) or vehicle for 30 minutes. B, ARVM maintained in culture were infected with AdV-GFP-HDAC5 (MOI 10 pfu/cell) alone or with AdV-Trx1 (MOI 100 pfu/cell) and exposed to ISO (1 nmol/L) or vehicle in controls (con) for 60 minutes. context, MEF2 activity in cardiac myocytes is known to be stimulated by multiple pathways, including MEF2 phosphorylation by p38 mitogen-activated protein kinase, 42 MEF2 acetylation by acetyltransferase p300, 43 and the nuclear export of other class II HDACs, such as HDAC4, after their phosphorylation by distinct stress-responsive kinases like CaMKII 8, 11, 44 and/or oxidation at regulatory cysteine residues. 15 Intriguingly, recent evidence suggests that selective activation of PKA is likely to decrease, rather than increase, MEF2 activity, through either the nuclear retention of HDAC5 after its phosphorylation at Ser280 13 and/or the proteolytic generation of a MEF2-inhibitory HDAC4 N-terminal fragment. 14 Our data support the notion that, in response to sustained ␤ 1 -AR stimulation in ARVM, MEF2-activatory mechanisms (such as the nuclear export of HDAC4 through CaMKII-mediated phosphorylation 8, 11, 44 and/or cysteine oxidation 15 and the nuclear export of HDAC5 through the phosphorylation-independent, oxidationmediated mechanism that has been revealed by the present study) are likely to predominate over such PKA-mediated, MEF2-inhibitory mechanisms. Figure 8 illustrates a working hypothesis, based on the novel findings of the present study and pertinent evidence from the literature on the neurohormonal regulation of HDAC5 nuclear localization. According to this hypothesis, ET1 stimulation per se is sufficient to induce HDAC5 nuclear export, through a mechanism that requires increased PKD activity and PKD-mediated HDAC5 phosphorylation at Ser259 and Ser 498. However, such a mechanism is unlikely to be of major importance in the presence of elevated sympathetic activity with intact ␤ 1 -AR signaling, as this would not only counteract HDAC5 phosphorylation (by inhibiting PKD activation and by inducing HDAC5 dephosphorylation) but also induce HDAC5 nuclear export by itself, through a phosphorylation-independent mechanism that involves ROS-mediated oxidation of regulatory cysteine residues. Figure 8 also illustrates potential PKA-mediated phosphorylation of HDAC5 at Ser280 and consequent HDAC5 nuclear retention, as recently proposed from studies with selective PKA activation (by cAMP or the adenylyl cyclase activator forskolin) in Cos7 cells and NRVM 13 ; however, in the present study, we find no evidence for such a mechanism in response to ␤-AR stimulation in ARVM.
The scheme illustrated in Figure 8 may also help explain why selective pharmacological inhibition of PKD, including by BPKDi, 27 has been found recently not to suppress pressure overload-induced hypertrophy in the rat in vivo, 27, 45 despite convincing evidence from in vitro models that have used agonists that selectively activate the PKC/PKD signaling axis as the hypertrophic stimulus. 28 It may be that dual inhibition of both phosphorylation-dependent and phosphorylationindependent pathways of HDAC5 nuclear export is required to achieve a therapeutic effect in vivo, particularly in models associated with elevated sympathetic activity and ␤ 1 -ARmediated induction of other MEF2-activatory mechanisms. Of potentially greater clinical relevance, based on our findings, is the possibility that PKD inhibition may be more efficacious in conjunction with ␤ 1 -AR antagonism. In this context, ␤ 1 -AR antagonists are among first-line therapy in the management of diseases that are associated with cardiac hypertrophy, such as postinfarction remodeling and heart failure. 46 Further investigation therefore appears warranted to test the potential synergistic effects of PKD inhibition in conjunction with ␤ 1 -AR antagonism in the attenuation of pathological cardiac remodeling in vivo, in appropriate models. Along similar lines, it is feasible that attenuation of ␤ 1 -AR-mediated derepression of MEF2 activity (by inhibition of both phosphorylation-dependent/CaMKII-driven and phosphorylation-independent/oxidation-mediated mechanisms of HDAC nuclear export) underlies the reversal of the fetal gene program that has been reported in patients with heart failure who show a favorable myocardial response to ␤ 1 -AR antagonist treatment 47 and that such effects may be further potentiated by concomitant suppression of disinhibited PKD activity.
